Moderna COVID-19 Vaccine (Spikevax) from Japan
An mRNA vaccine targeting the spike protein of SARS-CoV-2 for prevention of COVID-19 in humans. Classified in HTS 3002.41.00.00 as a human vaccine product for prophylactic immunization.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Pharmaceuticals: patented pharma from JP/EU/KR/CH/LI — 15% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Obtain FDA emergency use authorization documentation and import permit before shipment
• Label shipments clearly with biohazard warnings and maintain -70°C ultra-cold chain throughout import